ClinicalTrials.gg

Program

HB2198

A development code.

Its studies are mostly in Lupus Nephritis, led by Hinge Bio.

Furthest: phase 1, since Feb 18, 20261 company-led study, 1 open or runningNext primary completion: Oct 24, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hinge Bio11 open or runningphase 1since Feb 18, 2026Feb 18, 2026Oct 24, 2027phase 1 · NCT07491900

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 18, 2026First study: phase 1 study in Lupus NephritisFirst studyNCT07491900 · 30 planned · Australia

Ahead

  1. Oct 24, 2027Primary completion: phase 1 study in Lupus NephritisNCT07491900

TargetBeta

CD19 →MS4A1 →read by rule
“A Phase 1, Open Label Dose Escalating Study of HB2198, a Tetravalent Bispecific Anti-CD19/CD20 Antibody With Dual Fc Domains, in Patients With Moderately to Severely Active Systemic Lupus Erythematosus”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28
Autologous Anti-CD19/CD20 CAR-T Cells KITE-363ruleGilead Sciencesphase 23
prizloncabtagene autoleucelruleAbelZetaphase 22
GSK5926371GlaxoSmithKlinephase 22
Allogeneic Anti-CD19/CD20 CAR T-cells AVC-203ruleavencell-therapeutics-incphase 21
CT204V-CD19 × CD20ruleAstraZenecaphase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07491900Lupus Nephritis · Australia1RecruitingOct 24, 202730

How it is read

Names in the registry

  • “HB2198”, 1 entry

Codes read as this program: HB2198.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.